File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A global scientific strategy to cure hepatitis B

TitleA global scientific strategy to cure hepatitis B
Authors
Issue Date2019
PublisherElsevier: Lancet. The Journal's web site is located at http://www.sciencedirect.com/science/journal/24681253
Citation
The Lancet Gastroenterology & Hepatology, 2019, v. 4 n. 7, p. 545-558 How to Cite?
AbstractChronic hepatitis B virus (HBV) infection is a global public health challenge on the same scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE-HBV) is a coalition of experts dedicated to accelerating the discovery of a cure for chronic hepatitis B. Following extensive consultation with more than 50 scientists from across the globe, as well as key stakeholders including people affected by HBV, we have identified gaps in our current knowledge and new strategies and tools that are required to achieve HBV cure. We believe that research must focus on the discovery of interventional strategies that will permanently reduce the number of productively infected cells or permanently silence the covalently closed circular DNA in those cells, and that will stimulate HBV-specific host immune responses which mimic spontaneous resolution of HBV infection. There is also a pressing need for the establishment of repositories of standardised HBV reagents and protocols that can be accessed by all HBV researchers throughout the world. The HBV cure research agenda outlined in this position paper will contribute markedly to the goal of eliminating HBV infection worldwide.
Persistent Identifierhttp://hdl.handle.net/10722/275113
ISSN
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorRevill, PA-
dc.contributor.authorChisari, FV-
dc.contributor.authorBlock, JM-
dc.contributor.authorDandr, M-
dc.contributor.authorGehring, AJ-
dc.contributor.authorGuo, H-
dc.contributor.authorHu, J-
dc.contributor.authorKramvis, A-
dc.contributor.authorLampertico, P-
dc.contributor.authorJanssen, HLA-
dc.contributor.authorLevrero, M-
dc.contributor.authorLi, W-
dc.contributor.authorLiang, TJ-
dc.contributor.authorLim, SG-
dc.contributor.authorLu, F-
dc.contributor.authorPenicaud, MC-
dc.contributor.authorTavis, JE-
dc.contributor.authorThimme, R-
dc.contributor.authorArbuthnot, P-
dc.contributor.authorBoonstra, A-
dc.contributor.authorChang, KM-
dc.contributor.authorChen, PJ-
dc.contributor.authorGlebe, D-
dc.contributor.authorGuidotti, LG-
dc.contributor.authorFellay, J-
dc.contributor.authorFerrari, C-
dc.contributor.authorJansen, L-
dc.contributor.authorLau, DTY-
dc.contributor.authorLok, AS-
dc.contributor.authorMaini, MK-
dc.contributor.authorMason, W-
dc.contributor.authorMatthews, G-
dc.contributor.authorParaskevis, D-
dc.contributor.authorPeterse, J-
dc.contributor.authorRehermann, B-
dc.contributor.authorShin, EC-
dc.contributor.authorThompson, A-
dc.contributor.authorvan Bömmel, F-
dc.contributor.authorWang, FS-
dc.contributor.authorWatashi, K-
dc.contributor.authorYang, HC-
dc.contributor.authorYuan, Z-
dc.contributor.authorYuen, MF-
dc.contributor.authorBlock, T-
dc.contributor.authorMiller, V-
dc.contributor.authorProtzer, U-
dc.contributor.authorBréchot, C-
dc.contributor.authorLocarnini, S-
dc.contributor.authorPeters, MG-
dc.contributor.authorSchinazi, RF-
dc.contributor.authorZoulim, F-
dc.date.accessioned2019-09-10T02:35:42Z-
dc.date.available2019-09-10T02:35:42Z-
dc.date.issued2019-
dc.identifier.citationThe Lancet Gastroenterology & Hepatology, 2019, v. 4 n. 7, p. 545-558-
dc.identifier.issn2468-1253-
dc.identifier.urihttp://hdl.handle.net/10722/275113-
dc.description.abstractChronic hepatitis B virus (HBV) infection is a global public health challenge on the same scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE-HBV) is a coalition of experts dedicated to accelerating the discovery of a cure for chronic hepatitis B. Following extensive consultation with more than 50 scientists from across the globe, as well as key stakeholders including people affected by HBV, we have identified gaps in our current knowledge and new strategies and tools that are required to achieve HBV cure. We believe that research must focus on the discovery of interventional strategies that will permanently reduce the number of productively infected cells or permanently silence the covalently closed circular DNA in those cells, and that will stimulate HBV-specific host immune responses which mimic spontaneous resolution of HBV infection. There is also a pressing need for the establishment of repositories of standardised HBV reagents and protocols that can be accessed by all HBV researchers throughout the world. The HBV cure research agenda outlined in this position paper will contribute markedly to the goal of eliminating HBV infection worldwide.-
dc.languageeng-
dc.publisherElsevier: Lancet. The Journal's web site is located at http://www.sciencedirect.com/science/journal/24681253-
dc.relation.ispartofThe Lancet Gastroenterology & Hepatology-
dc.titleA global scientific strategy to cure hepatitis B-
dc.typeArticle-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1016/S2468-1253(19)30119-0-
dc.identifier.pmid30981686-
dc.identifier.pmcidPMC6732795-
dc.identifier.scopuseid_2-s2.0-85066415366-
dc.identifier.hkuros304383-
dc.identifier.volume4-
dc.identifier.issue7-
dc.identifier.spage545-
dc.identifier.epage558-
dc.identifier.isiWOS:000470096400018-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats